Published in Haematologica on April 15, 2008
Iron-chelating therapy for transfusional iron overload. N Engl J Med (2011) 3.92
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol (2012) 1.45
Towards explaining "unexplained hyperferritinemia". Haematologica (2009) 1.33
Liver iron content determination by magnetic resonance imaging. World J Gastroenterol (2010) 1.21
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica (2014) 1.00
The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients. Mediterr J Hematol Infect Dis (2016) 0.89
Heart and liver T2 assessment for iron overload using different software programs. Eur Radiol (2011) 0.87
Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements. Haematologica (2008) 0.86
The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients. Anemia (2011) 0.83
Hematopietic stem cell transplantation in thalassemia and related disorders. Mediterr J Hematol Infect Dis (2009) 0.82
Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging. J Cardiovasc Magn Reson (2011) 0.82
Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica (2009) 0.79
Measurement of liver iron concentration by MRI is reproducible. Biomed Res Int (2015) 0.78
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med (2015) 0.78
Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus (2012) 0.78
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century. Drugs (2016) 0.77
Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. Transfusion (2014) 0.75
Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients. Heliyon (2017) 0.75
Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study. Blood Transfus (2013) 0.75
Dual-energy X-ray absorptiometry with serum ferritin predicts liver iron concentration and changes in concentration better than ferritin alone. J Clin Densitom (2010) 0.75
MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer (2015) 0.75
Improved R2* liver iron concentration assessment using a novel fuzzy c-mean clustering scheme. BMC Med Imaging (2015) 0.75
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus (2012) 0.75
More pieces to the iron chelation puzzle. Transl Res (2010) 0.75
Validation of T2* in-line analysis for tissue iron quantification at 1.5 T. J Cardiovasc Magn Reson (2016) 0.75
Deferiprone challenge test for monitoring iron overload in hepatitis positive thalassemic major patients. Int J Clin Exp Med (2010) 0.75
Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population. Intern Emerg Med (2017) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet (2002) 4.19
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Iron-deficiency anemia. N Engl J Med (2015) 3.94
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab (2008) 3.78
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Hepcidin is decreased in TFR2 hemochromatosis. Blood (2004) 3.46
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med (2004) 3.26
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med (1994) 3.26
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica (2004) 2.32
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Beta-thalassemia. Genet Med (2010) 2.24
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe. Emerg Infect Dis (2003) 2.12
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood (2007) 2.10
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood (2007) 2.09
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
Purging iron from the heart. Br J Haematol (2004) 2.07
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J (2005) 1.95
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol (2007) 1.94
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood (2014) 1.87
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood (2013) 1.84
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83